Trial · NCT07903753
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feasibility: Participant Recruitment | Baseline | Rate of eligible screened Veterans and enrollment rate, used as an indicator of the reach and accessibility of RISE. |
| Primary | Feasibility: Study Retention | post-treatment (6 weeks), 3-month follow-up | Proportion of enrolled participants retained through study completion. |
| Primary | Feasibility: Number of Sessions Attended | 6 weeks | Average number of treatment sessions attended by participants in each arm, used as a behavioral indicator of treatment engagement. |
| Primary | Feasibility: Treatment Completion | 6 weeks | Proportion of participants who complete all six treatment sessions, used as a behavioral indicator of feasibility. |
| Primary | Feasibility: Study Withdrawals | post-treatment (6 weeks), 3-month follow-up | Number and proportion of participants who withdraw from the study prior to treatment completion. |
| Primary | Acceptability: Client Satisfaction Questionnaire-8 (CSQ-8) Score | 6 weeks | The CSQ-8 is an 8-item measure of participant satisfaction with treatment. A mean score of 24 or higher corresponds to sufficient overall treatment satisfaction. |
| Secondary | Treatment Acceptability and Adherence Scale (TAAS) | Baseline | A self-report measure of participants' expectations regarding the acceptability and credibility of their assigned treatment. |
| Secondary | Revised Vanderbilt Therapeutic Alliance Scale, Short Form (VTAS-R) | 6 weeks | A brief self-report measure of the quality of the therapeutic relationship between participant and therapist. |
| Secondary | Demographic Questionnaire | Baseline | Standard sociodemographic data including age, sex, race, ethnicity, and education. |
| Secondary | Treatment History Form | Baseline, post-treatment (6 weeks), 3-month follow-up | Self-report measure assessing prior and concurrent utilization of mental health and substance use treatment services. |
| Secondary | Combat Exposure Scale (CES) | Baseline | A brief self-report measure of combat-related exposure during military service. |
| Secondary | Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) | Baseline, post-treatment (6 weeks), 3-month follow-up | A structured clinical interview for diagnosing PTSD and assessing symptom severity according to DSM-5 criteria. |
| Secondary | Quick Structured Clinical Interview for DSM-5 Disorders (QuickSCID-5) | Baseline, post-treatment (6 weeks), 3-month follow-up | A structured diagnostic interview used to confirm presence of a substance use disorder and screen for other DSM-5 psychiatric disorders. |
| Secondary | Clinical Opiate Withdrawal Scale (COWS) | Baseline | A clinician-administered scale used to assess signs and symptoms of opioid withdrawal and screen for withdrawal risk. |
| Secondary | Clinical Institute Withdrawal Assessment (CIWA) | Baseline | A clinician-administered scale used to assess signs and symptoms of alcohol withdrawal and screen for withdrawal risk. |
| Secondary | PTSD Checklist for DSM-5 (PCL-5) | Baseline, post-treatment (6 weeks), 3-month follow-up | A 20-item self-report measure assessing the 20 DSM-5 symptoms of PTSD, used to track change in PTSD symptom severity. |
| Secondary | PTSD Checklist for DSM-5, Weekly | Week 1, 2, 3, 4, 5, 6 | An adapted version of DSM-5 adjusted to assess PTSD symptom severity on a weekly basis. |
| Secondary | Brief Addiction Monitor-Revised (BAM-R) | Baseline, post-treatment (6 weeks), 3-month follow-up | A self-report measure assessing substance use frequency, risk factors, and protective factors over the past 30 days. |
| Secondary | Brief Addiction Monitor for IOP (BAM-IOP) | Week 1, 2, 3, 4, 5, 6 | An abbreviated version of the BAM-R administered at each therapy session to monitor within-treatment substance use. |
| Secondary | Patient Health Questionnaire-9 (PHQ-9) | Baseline, post-treatment (6 weeks), 3-month follow-up | A 9-item self-report measure of depressive symptom severity. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07903753/registered